At Acceleron, we are committed to patient health, safety and well-being. We value the patient voice in all of our decisions, and focus our research and development on diseases where we can make a difference in the lives of patients with few or no effective therapeutic options. As part of the drug development process, we work closely with patients to help us better understand how disease affects their everyday lives, which enables us to find creative solutions for bringing potentially life-changing treatments to patients faster.
We are testing medicines in clinical trials to treat the chronic, sometimes debilitating anemias of the rare blood diseases MDS and beta-thalassemia and the neuromuscular disease facioscapulohumeral muscular dystrophy (FSHD).
You can view a full list of our clinical trials, here.